Creo Medical Group PLC

Creo Medical Group PLC

CREO · LSE · Healthcare / Medical Devices

10.25GBX+0.13 (+1.23%)

Price History

Full chart

Market Stats

Previous Close10.13
Open10.13
Day Range10.00 – 10.25
52-Week Range9.50 – 18.50
Volume529.41K
Market Cap43.34M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.04
Dividend Yield0.00%
Beta0.91
50-Day Avg12.63
200-Day Avg13.09

About

Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develops CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. It also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device. In addition, the company provides injection needles, hemostatic clips, snares, and forceps, as well as other products for gastroenterology, pulmonology, and urology. Further, it offers products for diagnostic, therapeutic, and hygiene purposes. Creo Medical Group PLC was founded in 2003 and is headquartered in Chepstow, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Craig Jonathan Gulliford
  • Employees104
  • HeadquartersCreo House, Chepstow, United Kingdom, NP16 5UH, UK
  • Websitehttps://www.creomedical.com

Leadership

  • Mr. Craig Jonathan GullifordCEO & Executive Director · b. 1970
  • Prof. Christopher Paul HancockFounder & CTO · b. 1967
  • Mr. Richard John Rees ACACFO & Executive Director · b. 1976
  • Mr. David Gerard WoodsChief Commercial Officer · b. 1965
  • Mr. Richard Gary CravenSecretary

Financials

Income Statement

Currency: GBP2014-02-282015-02-282016-02-292016-06-302017-06-302018-06-302018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue802.48K0534.67K508.22K00-13.47K9.43M25.16M27.17M4.00M4.00M6.00M
Growth (%)--100.00%--4.95%-100.00%---+69884.41%+166.85%+7.98%-85.28%0.00%+50.00%
Cost of Revenue-74.41K103.52K0142.42K0331.61K650.25K6.99M16.14M17.16M15.50M2.10M4.60M
Gross Profit802.48K-74.41K431.15K508.22K-142.42K225.00K-331.61K-636.77K2.44M9.02M10.01M15.30M1.90M1.40M
Gross Margin100.00%-80.64%100.00%----4726.29%25.86%35.86%36.84%382.50%47.50%23.33%
Operating Expense2.75M2.81M4.23M2.38M8.76M10.51M11.61M18.24M25.83M38.98M40.82M40.10M30.70M22.10M
Operating Income-1.95M-2.88M-3.80M-1.87M-8.90M-10.29M-11.94M-18.88M-23.39M-29.96M-30.81M-24.80M-28.80M-20.70M
Operating Margin-243.22%--711.10%-368.87%----140097.81%-248.09%-119.07%-113.39%-620.00%-720.00%-345.00%
EBITDA-1.89M-2.81M-3.70M--8.76M-9.97M-11.61M-17.96M-21.77M-27.54M-27.62M-20.70M-26.10M-19.70M
EBITDA Margin-235.47%--691.74%-----133300.63%-230.86%-109.46%-101.65%-517.50%-652.50%-328.33%
Net Income-1.70M-2.38M-3.33M-1.61M-7.77M-8.41M-9.87M-15.91M-20.32M-24.59M-26.94M-21.70M-28.70M5.30M
Net Income Margin-211.43%--622.74%-317.43%----118096.56%-215.46%-97.75%-99.14%-542.50%-717.50%88.33%
R&D--2.50M-3.58M-5.23M8.15M10.19M12.87M13.53M11.80M11.10M7.50M
R&D as % of Total Revenue--467.89%----60464.17%108.10%51.15%49.79%295.00%277.50%125.00%
Interest Expense43892.57K010.72K7.60K11.16K23.40K173.00K363.00K248.00K400.00K400.00K300.00K
Interest Expense % of Total Revenue0.00%-0.48%0.00%---173.66%1.83%1.44%0.91%10.00%10.00%5.00%

Balance Sheet

Currency: GBP2005-02-282006-02-282007-02-282008-02-292014-02-282015-02-282016-02-292016-06-302017-06-302018-06-302018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets5.00K161.00K257.00K171.00K1.62M1.04M3.75M2.42M16.12M9.62M49.75M88.26M92.46M100.61M75.34M76.60M65.00M59.10M
Total Liabilities17.00K164.00K245.00K58.00K250.20K295.98K532.79K788.81K1.47M2.29M2.03M5.60M29.66M27.29M25.93M16.80M22.60M9.10M
Total Equity--12.00K113.00K1.37M748.41K3.22M1.63M14.65M7.33M47.71M82.66M62.81M73.32M49.40M59.80M42.40M50.00M
Cash-148.00K66.00K99.00K887.65K305.24K2.57M823.28K13.69M6.37M44.59M81.05M45.09M43.53M13.10M3.00M8.70M12.40M
Total Debt------31.59K15.04K15.22K-433.48K717.09K12.36M10.56M11.70M8.30M4.40M4.10M
Net Debt-----887.65K-305.24K-2.54M--13.67M--44.16M-80.33M-32.74M-32.98M-1.40M5.30M-4.30M-8.30M

Cash Flow

Currency: GBP2014-02-282015-02-282016-02-292016-06-302017-06-302018-06-302018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.36M-2.27M-3.13M-1.64M-6.91M-7.00M-14.20M-11.54M-16.09M-25.98M-24.99M-21.60M-22.20M-18.60M
Investing Cash Flow-42.37K-57.74K-138.98K-98.42K-220.38K-825.93K-1.39M-1.12M-21.16M-7.87M-6.03M-18.30M15.30M19.40M
Financing Cash Flow2.09M1.75M5.53M-4.76K20.00M501.60K46.48M49.12M1.33M31.99M400.00K29.80M16.20M-700.00K
Capital Expenditure42.63K60.84K145.78K86.96K225.72K846.10K1.39M1.12M576.00K6.12M3.27M1.20M400.00K900.00K
Free Cash Flow-1.40M-2.34M-3.27M--7.14M-7.84M-15.58M-12.66M-16.66M-32.10M-28.26M-22.80M-22.60M-20.00M
Dividends Paid--5.51M-19.99M---------
FCF to OCF103.13%102.67%104.66%-103.26%112.09%109.78%109.69%103.58%123.56%113.10%105.56%101.80%107.53%
Dividend Paid to FCF---168.34%--279.94%---------

Earnings

Report DateFeb 3, 2017Nov 24, 2017Mar 20, 2018Sep 28, 2018May 13, 2019Sep 30, 2019May 27, 2020Sep 23, 2020Jun 5, 2021Sep 29, 2021Jun 2, 2022Sep 9, 2022Apr 26, 2023Sep 30, 2024May 19, 2025Sep 29, 2025Oct 6, 2025
EPS Estimate0.000.000.000.000.000.000.000.00-----0.000.00-0.00
EPS Actual-0.05-0.04-0.05-0.05-0.06-0.06-0.07-0.06-0.07-0.06-0.09-0.07-0.07-0.030.000.000.00
Surprise-----------------
Timing----------Pre-marketPre-marketPre-market--Pre-market-

Key Statistics & Ratios

Market Cap43.34M
Enterprise Value51.21M
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.19
Price / Book1.19
EPS-0.04
Book Value0.121
Revenue (TTM)7.00M
Gross Profit (TTM)2.90M
EBITDA-16.90M
Profit Margin-287.14%
Operating Margin-228.13%
Return on Equity-29.15%
Return on Assets-17.42%
Shares Outstanding449.14M
Shares Float382.64M
Beta0.91
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%